Excessive alcohol consumption, characteristic of alcohol use disorders, results in neurodegeneration and behav-25 ioral and cognitive impairments that are hypothesized to contribute to the chronic and relapsing nature of alco-26 holism. Therefore, the current study aimed to advance the preclinical development of transdermal delivery of 27 cannabidiol (CBD) for the treatment of alcohol-induced neurodegeneration. In Experiment 1, 1.0%, 2.5% and 28 5.0% CBD gels were evaluated for neuroprotection. The 5.0% CBD gel resulted in a 48.8% reduction in 29 neurodegeneration in the entorhinal cortex assessed by Fluoro-Jade B (FJB), which trended to statistical signifi-30 cance (p = 0.069). Treatment with the 5.0% CBD gel resulted in day 3 CBD plasma concentrations of 31100.0 ng/mL so this level was used as a target concentration for development of an optimized gel formulation.
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Excessive alcohol consumption, characteristic of alcohol use disorders, results in neurodegeneration and behav-25 ioral and cognitive impairments that are hypothesized to contribute to the chronic and relapsing nature of alco-26 holism. Therefore, the current study aimed to advance the preclinical development of transdermal delivery of 27 cannabidiol (CBD) for the treatment of alcohol-induced neurodegeneration. In Experiment 1, 1.0%, 2.5% and 28 5.0% CBD gels were evaluated for neuroprotection. The 5.0% CBD gel resulted in a 48.8% reduction in 29 neurodegeneration in the entorhinal cortex assessed by Fluoro-Jade B (FJB), which trended to statistical signifi-30 cance (p = 0.069). Treatment with the 5.0% CBD gel resulted in day 3 CBD plasma concentrations of 31100.0 ng/mL so this level was used as a target concentration for development of an optimized gel formulation.
32 Experiment 2 tested a next generation 2.5% CBD gel formulation, which was compared to CBD administration by 33 intraperitoneal injection (IP; 40.0 mg/kg/day). This experiment found similar magnitudes of neuroprotection fol-34 lowing both routes of administration; transdermal CBD decreased FJB+ cells in the entorhinal cortex by 56.1% 35 (p b 0.05), while IP CBD resulted in a 50.6% (p b 0.05) reduction in FJB+ cells. These results demonstrate the fea-36 sibility of using CBD transdermal delivery systems for the treatment of alcohol-induced neurodegeneration. 37 © 2013 Published by Elsevier Inc.
Introduction
43
Approximately 8.5% of the U.S. population currently meets the diag-44 nostic criteria for an alcohol use disorder (AUD; Hasin et al., 2007) . though four pharmacotherapy based interventions are approved in 46 the U.S. for the treatment of AUDs, these drugs have had limited efficacy in the patient population (Litten et al., 2012) . Additionally, these medi- Neuroprotective agents are hypothesized to have high therapeutic 55 utility for the treatment of AUDs (Crews, 1999) . Excessive alcohol in-56 take, characteristic of AUDs, results in neurodegeneration and cognitive 57 and behavioral impairment, effects which are hypothesized to influence 58 the transition to addiction (Koob and Le Moal, 1997; Crews, 1999; 59 Sullivan and Pfefferbaum, 2005) . Imaging studies have identified gross 60 anatomical abnormalities throughout the brains of human alcoholics in-61 cluding widespread disruption of white matter tracts, atrophied cortical 62 gray matter and increased cerebral spinal fluid filled space (Pfefferbaum 63 et al., 1992; Mechtcheriakov et al., 2007; Demirakca et al., 2011) . These 64 effects have also been observed in post-mortem studies showing signif-65 icant cortical neuronal loss in alcoholic brains (Harper and Kril, 1989; 66 Kril et al., 1997) , which is consistent with studies demonstrating long 67 term or permanent deficits in function (Stavro et al., 2012) . Some 68 brain structures appear to be more susceptible to the neurodegenera-69 tive effects of alcohol, including the frontal lobe (Kril et al., 1997; 70 Pfefferbaum et al., 1997; Qin and Crews, 2012) , temporal lobe 71 (Sullivan et al., 1995) and hippocampus (Sullivan et al., 1995) . The 72 aforementioned brain regions are involved in problem solving, atten-73 tion, information processing, learning and memory and behavioral con-74 trol, therefore it is not surprising that these functions are impaired in
75
AUDs (Stavro et al., 2012) . Importantly, a recent study described an as-76 sociation between reductions in cortical gray matter and risk for relapse 77 (Rando et al., 2011) properties and pH dependent CBD stability. The optimized formulation 177 described in Experiment 2 utilized only a 2.5% (w/w) CBD gel that 178 contained decreased levels of ethanol and an increase in water content.
179
Rats receiving gels had hair removed on their dorsal side using clippers 180 prior to binge treatment and 24 h before the first gel application. Rats 181 received CBD or vehicle starting after the third dose of ethanol by either 182 daily gel application (11:00 am) or IP injection (20 mg/kg) twice daily 183 (11:00 am and 11:00 pm; see Fig. 1A ). This IP dose was chosen based 184 off a previous study demonstrating CBD mediated neuroprotection 185 using a similar binge model (Hamelink et al., 2005 were collapsed. Regardless of treatment, all rats displayed similar Fig. 1 . Treatment regimen for cannabidiol neuroprotection studies. Rats were administered with ethanol according to a 4-day binge paradigm (A). In addition to receiving ethanol, rats were co-administered with CBD by IP injection twice daily (filled arrows) or topical gel formulation daily (open arrows). Plasma samples were collected on day 3 and prior to euthanasia from tail vein blood or trunk blood, respectively, for determination of blood ethanol concentrations and plasma CBD concentrations. Experiment groups with number of animals (B). Groups with matching symbols were collapsed prior to analysis.
intoxication behavior across the 4 days of binge treatment ( Fig. 2A) ethanol only (n = 13), vehicle IP (n = 12), CBD IP (n = 15), vehicle 333 gel (n = 7) and CBD gel (n = 9) groups across the 4 days of binge 334 treatment (Fig. 5A) . The grand mean intoxication score was 2.2 ± 0.1 335 out of 5 ( Fig. 5A insert) ; thus rats in this experiment were intoxicated 336 to the level of delayed righting reflexes and ataxia. Additionally,
337
each treatment group in this study received similar doses of 338 ethanol, which on average were 8.4 ± 0.2 g/kg/day (Fig. 5B ). The 339 grand mean peak BEC for this experiment was 380.4 ± 7.8 mg/dL, 340 which did not differ between groups (Fig. 5C ), confirming that the 341 drug treatments had no effect on the intoxicating effects or phar-342 macokinetics of ethanol. 
361
The mean plasma concentration from the 5% CBD gel group in Exper-362 iment 1 (Fig. 4 ) was used as a target concentration for Experiment 2 as Fig. 2 . Binge treatment data for Experiment 1. Rats were treated according to the modified Majchrowicz binge paradigm and administered with nothing, vehicle, 1%, 2.5% or 5.0% CBD gel formulations. Ethanol only and ethanol + vehicle groups were statically similar and therefore collapsed (black bars). Behavioral intoxication scores were similar across groups regardless of treatment (A, left axis), therefore each group received similar doses of alcohol (A, right axis). Although mean intoxication score for the 1.0% CBD gel group was significantly lower compared to the vehicle group (A inset), the average daily doses and blood ethanol concentrations did not differ between treatment groups (B-C). Collectively, the binge treatment data shows that CBD gel or vehicle gel treatment did not alter the pharmacokinetics or intoxicating effects of ethanol. *p b 0.05. Tx = treatment. were ineffective (Fig. 3) . The mean day 3 CBD plasma concentration 388 for the 5% CBD gel group was~100 ng/mL and was used as a target 389 concentration because neuroprotection outcomes were promising 390 for this group (Fig. 4) . In Experiment 2, an optimized formulation 391 was developed by AllTranz Inc. to efficiently deliver CBD at the target 392 plasma concentration while using less CBD (Fig. 7) . Importantly, the ward spiral to addiction (Koob and Le Moal, 1997; Crews, 1999 of CBD (Guimaraes et al., 1990; Malfait et al., 2000; Mechoulam et al., 433 2002; Mishima et al., 2005; Castillo et al., 2010) . In fact, a study by profiles affect CBD accumulation in the brain (Deiana et al., 2012) . 2.5% and 5.0% CBD groups during euthanasia (Fig. 4) . Although CBD 460 plasma levels were similar at euthanasia, only 5.0% CBD resulted in 461 promising neuroprotective effects (Fig. 3) . These observations highlight CBD (Mechoulam et al., 2002; Ren et al., 2009; Scuderi et al., 2009 ).
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For example CBD has anti-convulsant effects (acute withdrawal), Experiment 1 were consistently higher in ethanol treated rats (Fig. 4) ery. Therefore, future drug development studies are warranted and 
